ANIP Shares Drop on Strong Earnings, Backtests Tell a Different Story

ANI Pharmaceuticals (ANIP) delivered a sharp turnaround in profitability for Q4 2025, reporting a 367.5% increase in net income and a $1.22 EPS gain after a 2024 Q4 loss. The company reaffirmed its 2026 revenue guidance and outlined aggressive growth plans in rare diseases.

Revenue

ANI Pharmaceuticals’ Q4 revenue surged 29.6% to $247.06 million, driven by robust performance across key segments. Cortrophin Gel, the company’s flagship product, contributed $111.4 million in revenue, reflecting a 76% year-over-year increase. ILUVIEN added $19.8 million, while the generics division generated $100.8 million, marking 28% growth. The overall revenue expansion underscores strong demand for both branded and generic offerings.

Earnings/Net Income

The company returned to profitability with a $27.49 million net income in Q4 2025, a dramatic 367.5% improvement from a $10.28 million loss in the prior-year period. Earnings per share (EPS) rose to $1.22, reversing a $0.51 loss, representing a 341.5% positive swing. This turnaround highlights effective cost management and revenue diversification.

Price Action

Despite the strong earnings report, ANI Pharmaceuticals’ stock faced downward pressure, declining 3.07% in the latest trading day, 4.98% for the week, and 8.14% month-to-date.

Post-Earnings Price Action Review

The strategy of purchasing ANI Pharmaceuticals shares following a revenue decline quarter-over-quarter on the earnings release date and holding for 30 days generated an 86.51% return over three years, outperforming the 57.22% benchmark. While the 16.97% CAGR reflects consistent growth, the 42.56% maximum drawdown and 0.38 Sharpe ratio highlight significant volatility and risk.

CEO Commentary

CEO Nikhil Lalwani emphasized ANI’s transformation into a rare disease leader, citing 44% full-year revenue growth and 76% Cortrophin Gel expansion. Strategic priorities include expanding Cortrophin’s reach into nephrology, neurology, and acute gouty arthritis, alongside disciplined capital allocation to fund rare disease initiatives. Lalwani expressed confidence in a “virtuous cycle of growth” as generics and brands generate cash flows.

Guidance

ANI Pharmaceuticals reiterated 2026 guidance for net revenue of $1.055 billion–$1.115 billion (19%–26% YoY growth), with Cortrophin Gel revenue projected at $540 million–$575 million (55%–65% YoY growth). ILUVIEN revenue is forecasted at $78 million–$83 million. Adjusted non-GAAP EBITDA guidance stands at $275 million–$290 million.

Additional News

ANI Pharmaceuticals announced a 90-person sales force dedicated to acute gouty arthritis, leveraging Cortrophin Gel’s unique approval in this indication. CEO Nikhil Lalwani highlighted 15% of total Cortrophin prescriptions now targeting gout flares, with plans to expand awareness. CFO Stephen Carey reiterated 2026 guidance, noting Q1 seasonality but sequential growth through the year. The company also emphasized disciplined capital allocation to fund rare disease expansion while maintaining a strong cash position of $285.6 million.